Cabotegravir implant (Preclinical)

The design, formulation development, and initial pharmacokinetic studies in non-human primates (NHP) on a cabotegravir subcutaneous reservoir implant. Part of SLAP HIV research program at Northwestern University.

Results summary: In 90 days we observed implant B release 11% of the total cabotegravir load suggesting these implants could deliver cabotegravir for a year in the nonhuman primate model. All components used in this implant have a history of previous human use in parenteral products. The CAB drug loading is high (~87% by weight), allowing efficient use of the implant volume.

Last updated October 20, 2022